CLYM (Climb Bio, Inc.) Stock Financials & Earnings | Market Cap Arena

CLYM (Climb Bio, Inc.) Stock Financials & Earnings | Market Cap Arena

CLYMClimb Bio, Inc.

Mkt Cap$522M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$60M

EPS (TTM)-$0.89

Free Cash Flow (TTM)-$55M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Next: Q1 2026 · Mar 24

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$23M
Q2 23	$0	$0	-$7M
Q3 23	$0	$0	-$5M
Q4 23	$0	$0	-$5M
Q1 24	$0	$0	-$3M
Q2 24	$0	$0	-$56M
Q3 24	$0	$0	-$12M
Q4 24	$0	$0	-$11M
Q1 25	$0	$0	-$23M
Q2 25	$0	-$38K	-$11M
Q3 25	$0	$0	-$15M
Q4 25	$0	-$30K	-$19M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$15M	-$15M
Q2 23	-$8M	-$8M
Q3 23	$3M	$3M
Q4 23	-$947K	-$947K
Q1 24	-$2M	-$2M
Q2 24	-$667K	-$667K
Q3 24	-$8M	-$8M
Q4 24	-$6M	-$6M
Q1 25	-$15M	-$15M
Q2 25	-$11M	-$11M
Q3 25	-$12M	-$12M
Q4 25	-$16M	-$16M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$77K
Q3 25	$109K
Q4 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+78.5%
Q2 23	—	-51.0%
Q3 23	—	-42.8%
Q4 23	—	-46.4%
Q1 24	—	-87.2%
Q2 24	—	+739.6%
Q3 24	—	+134.6%
Q4 24	—	+113.0%
Q1 25	—	+666.0%
Q2 25	—	-81.1%
Q3 25	—	+26.9%
Q4 25	—	+76.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$10M	—
Q2 23	$777K	—
Q3 23	$656K	—
Q4 23	$1M	—
Q1 24	$465K	—
Q2 24	$512K	—
Q3 24	$3M	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$1M	—
Q3 25	$4M	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$6M	$18M	—
Q2 23	$4M	$3M	—
Q3 23	$3M	$2M	—
Q4 23	$3M	$2M	—
Q1 24	$1M	$2M	—
Q2 24	$53M	$4M	—
Q3 24	$6M	$5M	—
Q4 24	$6M	$5M	—
Q1 25	$17M	$6M	—
Q2 25	$7M	$4M	—
Q3 25	$9M	$6M	—
Q4 25	$14M	—	$6M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$34M	$75M	$109M
Q2 23	$25M	$77M	$103M
Q3 23	$57M	$50M	$107M
Q4 23	$93M	$14M	$107M
Q1 24	$105M	$0	$105M
Q2 24	$223M	$0	$223M
Q3 24	$146M	$47M	$193M
Q4 24	$87M	$64M	$151M
Q1 25	$29M	$69M	$98M
Q2 25	$23M	$62M	$85M
Q3 25	$26M	$61M	$87M
Q4 25	$36M	$65M	$101M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	27M	+0.6%
Q2 23	27M	+1.1%
Q3 23	27M	+0.9%
Q4 23	27M	+0.9%
Q1 24	28M	+1.2%
Q2 24	30M	+9.8%
Q3 24	67M	+120.8%
Q4 24	65M	-3.4%
Q1 25	67M	+4.2%
Q2 25	68M	+0.2%
Q3 25	68M	+0.6%
Q4 25	67M	-0.9%